Dexcom Files Routine 8-K, Confirms Nasdaq Listing
Ticker: DXCM · Form: 8-K · Filed: Jan 8, 2024 · CIK: 1093557
| Field | Detail |
|---|---|
| Company | Dexcom INC (DXCM) |
| Form Type | 8-K |
| Filed Date | Jan 8, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001, $1.030 b, $3.62 b, $4.15 billion, $4.35 billion |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: regulatory-filing, corporate-governance
TL;DR
**Dexcom filed a standard 8-K, no new news, just regulatory compliance.**
AI Summary
This 8-K filing from Dexcom, Inc. on January 8, 2024, is a routine administrative update, primarily confirming its status as a publicly traded company on the Nasdaq Global Select Market under the ticker DXCM. It doesn't contain new financial results or significant operational changes, but rather formalizes its current reporting obligations. For investors, this filing simply reaffirms Dexcom's ongoing compliance with SEC regulations, indicating business as usual without any immediate impact on stock valuation.
Why It Matters
This filing is a standard procedural update, confirming Dexcom's compliance with SEC reporting requirements and its listing on the Nasdaq Global Select Market. It signals stability rather than any new developments.
Risk Assessment
Risk Level: low — This 8-K is a purely administrative filing and does not introduce any new financial or operational risks.
Analyst Insight
This filing is purely administrative and provides no new information that would warrant an immediate investment action. Investors should continue to monitor for financial results or strategic announcements.
Key Numbers
- $0.001 — Par Value Per Share (the stated par value of Dexcom's Common Stock)
Key Players & Entities
- DEXCOM, INC. (company) — the registrant filing the 8-K
- Nasdaq Global Select Market (company) — the exchange where Dexcom's common stock is registered
- DXCM (company) — the trading symbol for Dexcom's common stock
- January 8, 2024 (date) — the date of the earliest event reported and filing date
- 000-51222 (dollar_amount) — Commission File Number
FAQ
What is the purpose of this specific 8-K filing by Dexcom, Inc.?
This 8-K filing is a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, primarily to report the 'Date of Earliest Event Reported' as January 8, 2024, and to confirm its registration of Common Stock, $0.001 Par Value Per Share, on the Nasdaq Global Select Market under the trading symbol DXCM.
On what stock exchange is Dexcom, Inc.'s common stock registered, according to this filing?
According to the filing, Dexcom, Inc.'s Common Stock, $0.001 Par Value Per Share, is registered on the Nasdaq Global Select Market.
What is the trading symbol for Dexcom, Inc. as stated in this 8-K?
The trading symbol for Dexcom, Inc. is DXCM, as indicated in the 'Title of Each Class' table within the filing.
What is the stated par value per share for Dexcom's Common Stock?
The stated par value per share for Dexcom's Common Stock is $0.001, as specified in the 'Title of Each Class' section.
Does this 8-K filing indicate that Dexcom, Inc. is an 'emerging growth company'?
No, the filing indicates with an unchecked box that Dexcom, Inc. is not an 'emerging growth company' as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Filing Stats: 994 words · 4 min read · ~3 pages · Grade level 11.2 · Accepted 2024-01-08 08:02:59
Key Financial Figures
- $0.001 — ange on Which Registered Common Stock, $0.001 Par Value Per Share DXCM Nasdaq Global
- $1.030 b — ber 31, 2023 is expected to be at least $1.030 billion, an increase of 26% over the four
- $3.62 b — revenue is expected to be approximately $3.62 billion, an increase of 24% over 2022. F
- $4.15 billion — ange for total revenue of approximately $4.15 billion to $4.35 billion. The fourth quarter a
- $4.35 billion — venue of approximately $4.15 billion to $4.35 billion. The fourth quarter and fiscal year 20
Filing Documents
- dxcm-20240108.htm (8-K) — 32KB
- a991jpmorgan182024.htm (EX-99.1) — 13KB
- dxcm-20240108_g1.jpg (GRAPHIC) — 108KB
- 0001093557-24-000003.txt ( ) — 422KB
- dxcm-20240108.xsd (EX-101.SCH) — 2KB
- dxcm-20240108_lab.xml (EX-101.LAB) — 24KB
- dxcm-20240108_pre.xml (EX-101.PRE) — 12KB
- dxcm-20240108_htm.xml (XML) — 3KB
02. RESULTS OF OPERATIONS AND FINANCIAL CONDITION
ITEM 2.02. RESULTS OF OPERATIONS AND FINANCIAL CONDITION. In connection with remarks to be made at the J.P. Morgan 42nd Annual Healthcare Conference on Monday, January 8, 2024, beginning at 12:45 p.m. (Eastern Time), DexCom, Inc. ("Dexcom") Chairman, President and Chief Executive Officer, Kevin Sayer, will report that preliminary, unaudited revenue for the fourth quarter ended December 31, 2023 is expected to be at least $1.030 billion, an increase of 26% over the fourth quarter of 2022. For fiscal year 2023, total preliminary, unaudited revenue is expected to be approximately $3.62 billion, an increase of 24% over 2022. Finally, Mr. Sayer will provide Dexcom's initial financial outlook for fiscal year 2024, including an anticipated range for total revenue of approximately $4.15 billion to $4.35 billion. The fourth quarter and fiscal year 2023 preliminary unaudited financial results contained in Mr. Sayer's presentation and in this Current Report on Form 8-K are subject to finalization in connection with the preparation of Dexcom's Annual Report on Form 10-K for the twelve months ended December 31, 2023. This Current Report on Form 8-K and the press release contain, and Mr. Sayer's presentation on January 8, 2024 will contain, forward-looking statements concerning Dexcom's or its management's intentions, beliefs, expectations and strategies for the future, including those related to Dexcom's preliminary, unaudited revenue for the fourth quarter of and the full fiscal year 2023, and estimated total revenue, Non-GAAP Gross Profit Margin and Non-GAAP Operating Margin, for fiscal 2024, expected growth rates as compared to the year ended December 31, 2022, as well as the anticipated launch of Stelo. Because such statements deal with future events, they are subject to various risks and uncertainties. The risks and uncertainties that may cause actual results to differ materially from Dexcom's current expectations are more fully described in Dexcom's Annual Report on Fo
01. FINANCIAL STATEMENTS AND EXHIBITS
ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS. (d) Exhibits. Number Description 99.1 Press release dated January 8, 2024 announcing the preliminary financial results for the quarter and year ended December 31, 2023 and certain other information 104 Cover Page Interactive Data File (formatted as Inline XBRL)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. DEXCOM, INC. By: /s/ JEREME M. SYLVAIN Jereme M. Sylvain Executive Vice President and Chief Financial Officer (Principal Financial and Accounting Officer) Date: January 8, 2024